Cargando…
Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients
OBJECTIVES: The primary objective was to evaluate long-term treatment persistence and safety of natalizumab in Finnish multiple sclerosis patients. The secondary objectives were to assess patient characteristics, use of natalizumab-related safety protocol, and treatment persistence in patients with...
Autores principales: | Verkkoniemi-Ahola, Auli, Hartikainen, Päivi, Hassi, Katja, Kuusisto, Hanna, Lahdenperä, Sanni, Mehtälä, Juha, Viitala, Matias, Ylisaukko-oja, Tero, Soilu-Hänninen, Merja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552456/ https://www.ncbi.nlm.nih.gov/pubmed/37808458 http://dx.doi.org/10.1177/20552173231204466 |
Ejemplares similares
-
Medication adherence/persistence among patients with active multiple sclerosis in Finland
por: Lahdenperä, Sanni, et al.
Publicado: (2020) -
Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study
por: Hänninen, K., et al.
Publicado: (2021) -
Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis
por: Sipilä, Jussi OT, et al.
Publicado: (2023) -
Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2019) -
Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2020)